Search
Promethazine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175084Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeAlimemazine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175089Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeZiprasidone H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175141Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeAcrivastine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175099Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeVorapaxar Action Pathway
smpdb.ca/view/SMP0126558Drug actionVorapaxar inhibits protease-activated receptor 1 (PAR-1), which is a G protein-coupled receptor that is expressed on the platelet. Inhibition of PAR-1 prevents platelet aggregation and activation.
Enzymes: Protein kinase C alpha type, Amyloid beta A4 precursor protein-binding family B member 1-interacting proteinClozapine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175109Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeOlopatadine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175127Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeOrphenadrine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175111Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeDexchlorpheniramine maleate H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175138Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeCarbinoxamine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175080Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha type